Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Julphar
Farmers Insurance
Teva
McKinsey
Johnson and Johnson
Novartis
Queensland Health
Argus Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,998,953

« Back to Dashboard

Summary for Patent: 7,998,953
Title:Use of inhibitors of the renin-angiotensin system
Abstract: It has been found that inhibitors of the rennin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
Inventor(s): Montgomery; Hugh Edward (London, GB), Martin; John Francis (London, GB), Erusalimsky; Jorge Daniel (London, GB)
Assignee: Ark Therapeutics Group, p.l.c. (London, GB)
Application Number:11/119,181
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,998,953

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MICARDIS telmisartan TABLET;ORAL 020850-002 Nov 10, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,998,953

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9722026.3Oct 17, 1997
United Kingdom9810855.8May 20, 1998

Non-Orange Book US Patents Family Members for Patent 7,998,953

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,071,183 Use of inhibitors of the renin-angiotensin system ➤ Subscribe
8,003,679 Use of inhibitors of the renin-angiotensin system ➤ Subscribe
8,604,070 Use of inhibitors of the renin-angiotensin system ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,998,953

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 9453398 ➤ Subscribe
Australia 742506 ➤ Subscribe
Canada 2306216 ➤ Subscribe
Canada 2677910 ➤ Subscribe
China 1279606 ➤ Subscribe
China 1123342 ➤ Subscribe
Germany 69838042 ➤ Subscribe
Denmark 1023067 ➤ Subscribe
Denmark 1498124 ➤ Subscribe
European Patent Office 1023067 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
McKinsey
Medtronic
US Army
Daiichi Sankyo
Queensland Health
Julphar
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot